Nuclidium, a radiopharmaceutical company based in Switzerland and Germany, has raised €84 million (US$98.4 million) in a series B financing round.

The funding, announced on July 10, 2025, was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR.

Additional participation came from DeepTech & Climate Fonds, Bayern Kapital, and NRW.BANK.

The funds will support the clinical development of Nuclidium’s Copper-61/Copper-67 theranostic pipeline for oncology applications.

As part of the financing round, Daniel Parera, MD, Regina Hodits, PhD, and Liliana Nordbakk will join NUCLIDIUM’s Board of Directors.

The company also plans to expand its global production and manufacturing network for diagnostics and therapeutics.

The company also intends to expand its international team and enhance collaborations with academic and healthcare institutions in Europe and North America.

Nuclidium’s platform uses Copper-61 for diagnostics and Copper-67 for therapeutics, aiming to improve existing radiotheranostics.

🔗 Source: Nuclidium

🧠 Food for thought

1️⃣ Copper radioisotopes represent a breakthrough in a century-long evolution of nuclear medicine

Nuclidium’s focus on copper-based radiopharmaceuticals builds upon nuclear medicine foundations established over 120 years ago, beginning with Wilhelm Roentgen’s X-ray discovery in 1895 and the Curies’ groundbreaking work on radioactivity 1.

While traditional radiopharmaceuticals have enabled approximately 20 million nuclear medicine procedures annually in the U.S. alone, copper isotopes offer distinct advantages over conventional options 2.

The global radiopharmaceutical market, valued at $9.1 billion in 2023, is projected to reach $26.5 billion by 2031, reflecting growing recognition of their clinical value in precision medicine 3.

Copper isotopes are particularly valuable because they enable the same radiopharmaceutical structure to be labeled with different isotopes (copper-61 for diagnostics, copper-67 for therapy), creating more efficient “theranostic” pairs that can both detect and treat disease 4.

This approach represents a significant advancement over traditional nuclear medicine techniques, which often required different compounds for diagnosis versus treatment.